Health Care Services

Hims & Hers Health

Bank of America Lowers Hims & Hers Price Target to $28 from $30

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers debuts first AI agent, Labs AI

Law Firm Investigates Hims & Hers Health for Potential Corporate Wrongdoing

Hims & Hers Health Reports Net Loss in Q1 2026 Results, Leading to Stock Volatility

Hims & Hers Health expects to close its acquisition of Eucalyptus in mid-2026.

Investment group Susquehanna discloses a 6.5% passive stake in Hims & Hers

Hims & Hers reports Q1 earnings with an unexpected loss of $0.40 per share, but raises full-year revenue forecast

Capital World Investors discloses its stake in Hims & Hers

BofA Securities Lowers Price Target for Hims & Hers Health, Maintains Neutral Rating

Needham & Company Raises Hims & Hers Price Target Despite Earnings Miss

Hims & Hers Health Average Target Price Rises to $27.51

Morgan Stanley and Citibank Maintain Hold Rating on Hims & Hers Health

Hims & Hers Health Pivots to Branded Weight-Loss Drugs, International Revenue Grows Nearly Tenfold

HIMS Options Volume and Open Interest

JPMorgan Downgrades Hims & Hers Health's Price Target to $33

Hims & Hers Health released FY2026 Q1 earnings on May 11 After-Market (EST), actual revenue USD 608.1M (forecast USD 616.85M), actual EPS USD -0.4033 (forecast USD 0.0342)

Hims & Hers Health Anticipates Revenue Growth in Q2

Hims & Hers Health Misses Q1 Earnings Estimates, Shares Fall

Media reports on Hims & Hers Health's launch of an AI-powered care assistant named Labs AI

InMed Pharmaceuticals

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Amesite

Meiwu Tech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

NextNRG

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

Hims & Hers Health, Inc. (HIMS.US) Q1 2026 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q4 2025 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q3 2025 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q2 2025 Earnings Conference Call

HIMS

HIMZ

Hims has priced an upsized $350 million offering of 0.00% convertible senior notes due 2032, increased from $300 million. The funds will support international expansion and AI investments, with estimated net proceeds of approximately $338.5 million. The initial conversion rate is set at 33.8590 shares per $1,000 principal, reflecting a ~32.5% premium to the recent stock price.

TradingView

Defiance Daily Target 2X Long HIMS ETF

Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M

Hims & Hers Health has upsized its private offering of 0% convertible senior notes to $350 million, increased from $300 million. The offering, due June 1, 2032, includes a 13-day option for initial purchasers to buy an additional $52.5 million. Proceeds will fund capped call transactions, support the acquisition of Eucalyptus, and cover general corporate purposes. The offering is expected to close Thursday.

Fidelity

iShares US Healthcare Providers

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Hims & Hers Health Prices Upsized $350 Million Notes Offering

On May 18, Eastern Time, Hims & Hers Health options saw a total of 131820 contracts traded, with calls accounting for 68% and puts making up 31%.

Options Flow

Trending | HIMS Plummets 11% on Monday, Some Put options Soar 550%

Hims & Hers Health(HIMS.US)

Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M

Hims & Hers Health Prices Upsized $350 Million Notes Offering

Trending | HIMS Plummets 11% on Monday, Some Put options Soar 550%